fool – Neuroscience

Demand for Ozempic and Wegovy is reaching new heights. Here’s why it can go even higher. | The motley fool

October 25, 2023 by Wilma

Demand for Ozempic and Wegovy is reaching new heights. Here's why it can go even higher. | The motley fool

Ozempic and Wegovy. These are the two drugs that are the focus of any income or press release coming fromNovo Nordisk(NVO -0.09%). The Danish company struck gold not only with a cutting-edge diabetes drug in Ozempic, but also with an impressive weight loss treatment in Wegovy. Both drugs actually help… Continue Reading Demand for Ozempic and Wegovy is reaching new heights. Here’s why it can go even higher. | The motley fool

1 Big risk facing Ozempic, Wegovy and other GLP-1 weight loss drugs | The motley fool

October 14, 2023 by Wilma

1 Big risk facing Ozempic, Wegovy and other GLP-1 weight loss drugs | The motley fool

Weight loss medications have grown in popularity in recent years. People even use a drug like Ozempic, although it is only approved for diabetes, simply because it helps them lose weight. In the last three months of 2022 alone, more than 9 million prescriptions for weight loss drugs were dispensed… Continue Reading 1 Big risk facing Ozempic, Wegovy and other GLP-1 weight loss drugs | The motley fool